For U.S. Healthcare Professionals Only

About VARIZIG®

Reducing Varicella Severity with VARIZIG

VARIZIG [Varicella-Zoster Immune Globulin (Human)] is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient groups, including immunocompromised children and adults, newborns, and pregnant women.

VARIZIG is intended to reduce the severity of chickenpox infections in these patients.1

VARIZIG is a hyperimmune product that contains antibodies specific to the Varicella-Zoster Virus (VZV), the viral infection known as chickenpox.1

The Centers for Disease Control (CDC) recommends VARIZIG for post-exposure prophylaxis of varicella for persons at high-risk of severe disease who lack evidence of immunity to varicella.

VARIZIG is approved for administration as soon as possible after exposure to VZV, ideally within 96 hours (4 days), and can be given up to 10 days post-exposure.2

Click here for the CDC recommendation for the use of VARIZIG

Indication and Usage1

VARIZIG is a Varicella Zoster Immune Globulin (Human) indicated for post-exposure prophylaxis in high-risk individuals.

High-risk groups include immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neon huihiuh uihiuhi hiuhi u s

sdsd sdfsdf sdfsdfs sfsdfsd sdfs  sdfsdfh fgfg dfgdfgdfgdfg

 

 

 

dfgdsfjglskjdfg

sflgksdlfkgjlsdfg